
About T3D Therapeutics
T3D Therapeutics is a Healthcare company based in Durham (United States) founded in 2013 by John Didsbury. Therapeutics for neurodegenerative diseases, including Alzheimers, are developed. T3D Therapeutics has raised $33.02 million across 15 funding rounds from investors including HHS, NCBiotech and National Institute on Aging. Its chief executive, as recorded, is John Didsbury. T3D Therapeutics offers products and services including T3D-959. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is T3D Therapeutics, Inc. Its competitors include Alzheon, Longeveron and Eikonizo; 3 of its 3 listed competitors have raised funding.
Company details
T3D Therapeutics was founded in 2013 and is based in Durham, United States. Operations focus on the biotechnology sector, with emphasis on creating treatments for neurodegenerative conditions. A key product, T3D-959, is designed to address multiple Alzheimers disease pathologies, such as beta-amyloid and tau pathways, along with insulin and IGF-resistance mechanisms. Development efforts target core disease triggers in this field.
- Headquarters Durham, United States
- Founders John Didsbury
- SectorsHealthcare
- Website t3dtherapeutics.com
- Social LinkedIn X Facebook
- Legal Name T3d Therapeutics, Inc.
- Total Equity Funding$33.02M (USD)
in 15 rounds
- Latest Funding Round$2.26M (USD), Grant
Aug 2023
- InvestorsHHS
& 2 more
Products & Services of T3D Therapeutics
T3D Therapeutics offers a comprehensive portfolio of products and services, including T3D-959.
Targets brain metabolism to treat Alzheimer's and improve cognitive function.
Funding Insights of T3D Therapeutics
T3D Therapeutics has successfully raised a total of $33.02M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $2.26 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.02M
- Total Rounds 15
- Last Round Grant β $2.26M
- First Round $437,000
(Aug 2013)
- Investors Count 3
Latest 10 of 15 funding rounds of T3D Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $2.26M | Grant | β | β | |
| Sep 2022 | $1.46M | Grant | β | β | |
| Sep 2022 | $6M | Series B | β | β | β |
| Oct 2019 | $15M | Series B | β | NIA | β |
| May 2019 | $9M | Grant | β | β | |
| May 2019 | $20.37M | Grant | β | β | |
| Mar 2018 | $6M | Series A | β | β | β |
| Jan 2018 | $711,270 | Series A | β | β | β |
| Jul 2016 | $3M | Series A | β | β | β |
| Mar 2016 | $1.21M | Series A | β | β | β |
3 investors in total: 3 institutional.
Investors in T3D Therapeutics
T3D Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NCBiotech and National Institute on Aging.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Research and information on aging are provided by this institute. | nia.nih.gov | Bethesda, United States |
Investor details for T3D Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of T3D Therapeutics
18 people are tracked at T3D Therapeutics (4 in leadership, 13 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
John Didsbury | Founder & CEO | Leadership |
Stan Chamberlain | Chief Scientific Officer | Leadership |
Blake Swearingen | Director, Clinical Development | Leadership |
Warren Strittmatter | Chief Medical Officer | Leadership |
Michael Weiner | Advisor | Board & advisors |
John A. Golden | Director | Board & advisors |
Roger Bullock | Advisor | Board & advisors |
Martin Farlow | Advisor | Board & advisors |
Marwan Sabbagh | Advisor | Board & advisors |
Pierre Tariot | Advisor | Board & advisors |
Charles Lineberry | Director | Board & advisors |
Thomas G. Mendell | Director | Board & advisors |
Roberta Brinton | Advisor | Board & advisors |
Suzanne Craft | Advisor | Board & advisors |
Barry Buzogany | Director | Board & advisors |
Michael Heneka | Advisor | Board & advisors |
David B. Keim | Director | Board & advisors |
Hoda Gabriel | Consultant | Team |
Complete people profiles for T3D Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of T3D Therapeutics
3 dated milestones of T3D Therapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded T3D Therapeutics is founded.
- Funding First funding round of $437K.
- Funding Latest funding round, Grant, of $2.3M.
Competitors of T3D Therapeutics
T3D Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Alzheon, Longeveron and Eikonizo.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alzheon.com | 2013 | Framingham, United States | $195.25M | Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed. | ||
| longeveron.com | 2014 | Miami, United States | $1.05M | 23 | Cellular therapies for aging-related and life-threatening conditions are developed. | |
| eikonizo.com | 2017 | Cambridge, United States | $2.37M | 7 | Brain-penetrant small molecule therapeutics for neurodegenerative diseases are developed. |
Detailed competitors of T3D Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of T3D Therapeutics
The website of T3D Therapeutics (t3dtherapeutics.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▲ 173% vs previous month
Top companies in Neurology
3 companies that operate in the same segment as T3D Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about T3d Therapeutics
Complete news archive for T3D Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about T3D Therapeutics
T3D Therapeutics was founded in 2013.
T3D Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
John Didsbury is the CEO of T3D Therapeutics, as recorded in our data. They have also founded this company.
T3D Therapeutics is a funded company, having raised a total of $33.02M across 15 funding rounds to date. The company's 1st funding round was a Series A of $1.21M, raised on Aug 2013.
T3D Therapeutics was founded in 2013 and is based in Durham, United States. Operations focus on the biotechnology sector, with emphasis on creating treatments for neurodegenerative conditions. A key product, T3D-959, is designed to address multiple Alzheimers disease pathologies, such as beta-amyloid and tau pathways, along with insulin and IGF-resistance mechanisms. Development efforts target core disease triggers in this field.
T3D Therapeutics's top competitors include Alzheon, Longeveron and Eikonizo.
T3D Therapeutics offers T3D-959.
T3D Therapeutics has 3 investors. Key investors include HHS, NCBiotech, and National Institute on Aging.
T3D Therapeutics operates through T3d Therapeutics, Inc..
